FGF2 and hepatocellular carcinoma: AMP had anti-angiogenesis activity by inhibiting the secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) from human hepatocellular carcinoma cells in vitro and also inhibited the growth of human hepatocellular carcinoma in mice [11].